Aberrant methylation during cervical carcinogenesis.
暂无分享,去创建一个
[1] J. Minna,et al. Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. , 2001, Journal of the National Cancer Institute.
[2] A. Maitra,et al. Molecular Papanicolaou tests in the twenty-first century: molecular analyses with fluid-based Papanicolaou technology. , 2000, American journal of obstetrics and gynecology.
[3] M. Widschwendter,et al. Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer. , 2000, Journal of the National Cancer Institute.
[4] R. Momparler,et al. DNA methylation and cancer , 2000, Journal of cellular physiology.
[5] S. Groshen,et al. Progressive increases in de novo methylation of CpG islands in bladder cancer. , 2000, Cancer research.
[6] M. Caligiuri,et al. Aberrant CpG-island methylation has non-random and tumour-type–specific patterns , 2000, Nature Genetics.
[7] J. Minna,et al. ACCELERATED DISCOVERY Promoter Methylation and Silencing of the Retinoic Acid Receptor- Gene in Lung Carcinomas , 2000 .
[8] T. Enomoto,et al. FHIT alterations in cancerous and non‐cancerous cervical epithelium , 2000, International journal of cancer.
[9] Taylor Murray,et al. Cancer statistics, 2000 , 2000, CA: a cancer journal for clinicians.
[10] J. Herman,et al. Advances in Brief Inactivation of the DNA Repair Gene O 6-Methylguanine-DNA Methyltransferase by Promoter Hypermethylation Is Associated with G to A Mutations in Kras in Colorectal Tumorigenesis 1 , 2000 .
[11] J. Herman,et al. In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[12] J. Shepherd,et al. FIGO staging of gynecologic cancer , 1999 .
[13] C. Croce,et al. Role of FHIT in Human Cancer , 1999 .
[14] G. Deng,et al. Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. , 1999, Cancer research.
[15] A. Batova,et al. Methylation of p16INK4A in primary gynecologic malignancy. , 1999, Cancer letters.
[16] J. Herman,et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. , 1999, Cancer research.
[17] A. Miller,et al. Natural history of dysplasia of the uterine cervix. , 1999, Journal of the National Cancer Institute.
[18] J. Donnez. Today's treatments: medical, surgical and in partnership , 1999, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[19] R. Strange,et al. The glutathione S-transferases: influence of polymorphism on cancer susceptibility. , 1999, IARC scientific publications.
[20] J. Shepherd,et al. FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. , 1999, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[21] J. Herman,et al. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. , 1999, Cancer research.
[22] J. Herman,et al. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. , 1998, Cancer research.
[23] Manel Esteller,et al. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas , 1998, Oncogene.
[24] J. Herman,et al. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. , 1998, Cancer research.
[25] D. Sinnett,et al. Demethylation by 5-aza-2´-deoxycytidine of specific 5-methylcytosine sites in the promoter region of the retinoic acid receptor ß gene in human colon carcinoma cells , 1998, Anti-cancer drugs.
[26] E Gabrielson,et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[27] H. Harada,et al. Methylation of the 5' CpG island of the FHIT gene is closely associated with transcriptional inactivation in esophageal squamous cell carcinomas. , 1998, Cancer research.
[28] J. Herman,et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[29] R. Jaenisch,et al. RNA and the Epigenetic Regulation of X Chromosome Inactivation , 1998, Cell.
[30] J. Minna,et al. Abnormalities of fragile histidine triad genomic and complementary DNAs in cervical cancer: association with human papillomavirus type. , 1998, Journal of the National Cancer Institute.
[31] J. Herman,et al. Alterations in DNA methylation: a fundamental aspect of neoplasia. , 1998, Advances in cancer research.
[32] Mimi C. Yu,et al. Alterations in DNA methylation are early, but not initial, events in ovarian tumorigenesis. , 1997, British Journal of Cancer.
[33] P. Magnusson,et al. Analysis of loss of heterozygosity in microdissected tumor cells from cervical carcinoma using fluorescent dUTP labeling of PCR products. , 1996, BioTechniques.
[34] J. Herman,et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[35] S. Baylin,et al. Hypermethylation of chromosome 17P locus D17S5 in human prostate tissue. , 1996, The Journal of urology.
[36] R. Kurman,et al. BLAUSTEIN'S PATHOLOGY OF THE FEMALE GENITAL TRACT , 1995 .
[37] F. Kaye,et al. CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2'deoxycytidine. , 1995, Oncogene.
[38] J. Herman,et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.
[39] V. Moreno,et al. Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective , 1995 .
[40] S. Baylin,et al. Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. , 1995, Cancer research.
[41] J. Willson,et al. O6-alkylguanine-DNA alkyltransferase. A target for the modulation of drug resistance. , 1995, Hematology/oncology clinics of North America.
[42] V. Moreno,et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. , 1995, Journal of the National Cancer Institute.
[43] J. Herman,et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[44] A. Giuliano,et al. Global DNA hypomethylation increases progressively in cervical dysplasia and carcinoma , 1994, Cancer.
[45] Chi-An Chen,et al. The genotypes and prognostic significance of human papillomaviruses in cervical cancer , 1994, International journal of cancer.
[46] T. Wright,et al. Precancerous Lesions of the Cervix , 1994 .
[47] Rudolf Jaenisch,et al. Role for DNA methylation in genomic imprinting , 1993, Nature.
[48] T. Sakai,et al. CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene. , 1993, Oncogene.
[49] R. Jaenisch,et al. DNA methylation, genomic imprinting, and mammalian development. , 1993, Cold Spring Harbor symposia on quantitative biology.
[50] Rudolf Jaenisch,et al. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality , 1992, Cell.
[51] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[52] K. Hagino-Yamagishi,et al. [Oncogene]. , 2019, Gan to kagaku ryoho. Cancer & chemotherapy.
[53] R. Richart,et al. Natural history of cervical intraepithelial neoplasia , 1967 .